Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer

  • Technology appraisal guidance
  • TA91
  • Published: 

This guidance has been updated and replaced by NICE technology appraisal guidance 389.